Evidence map›Paper›PMID 30443858›Full record

ArticlePharmaceutical research2018

Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer.

Larissa Gomes Dos Reis, Maree Svolos, Lyn M Moir, Rima Jaber, Norbert Windhab, Paul M Young, Daniela Traini

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Larissa Gomes Dos ReisRespiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, Sydney University, 431 Glebe Point Road, Glebe, Camperdown, NSW, 2037, Australia. larissa.gomes@sydney.edu.au.
Maree SvolosRespiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, Sydney University, 431 Glebe Point Road, Glebe, Camperdown, NSW, 2037, Australia.
Lyn M MoirRespiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, Sydney University, 431 Glebe Point Road, Glebe, Camperdown, NSW, 2037, Australia.
Rima JaberEvonik Industries AG, Kirschenallee, 64293, Darmstadt, Germany.
Norbert WindhabEvonik Industries AG, Kirschenallee, 64293, Darmstadt, Germany.
Paul M YoungRespiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, Sydney University, 431 Glebe Point Road, Glebe, Camperdown, NSW, 2037, Australia.
Daniela TrainiRespiratory Technology, Woolcock Institute of Medical Research and Discipline of Pharmacology, Sydney Medical School, Sydney University, 431 Glebe Point Road, Glebe, Camperdown, NSW, 2037, Australia.

Funding

Australian Research Council LP140100181Governo Brasil (BR) Capes 99999.013454/2013-07
6 · The paper itself

Abstract

purposeIn this study, a cell penetrating peptide was used as an uptake enhancer for pDNA delivery to the lungs.

methodsPolyplexes were prepared between pDNA and CPP. Intracellular delivery of pDNA was assessed in both alveolar (A549) and bronchial (Calu-3) epithelial cells. Aerosol delivery was investigated using a mesh nebulizer.

resultsEfficient intracellular delivery of pDNA occurs in both A549 and Calu-3 cells when delivered as polyplexes. Protection against nucleases and endosomal escape mechanism occurs when pDNA is formulated within the polyplexes. For aerosol delivery, 1% (w/v) mannitol was able to protect naked DNA structure during nebulization with a significant increase in fine particle fraction (particles <5 μm). The structure of polyplexes when delivered via a mesh nebulizer using 1% (w/v) mannitol could partially withstand the shear forces involved in aerosolization. Although some loss in functionality occurred after nebulization, membrane-associated fluorescence was observed in A549 cells. In Calu-3 cells mucus entrapment was a limiting factor for polyplex delivery.

conclusionsThe presence of CPP is essential for efficient intracellular delivery of pDNA. The polyplexes can be delivered to lung epithelial cells using mesh nebulizer. The use of different excipients is essential for further optimization of these delivery systems.

Indexed as

Administration, InhalationAerosolsAlveolar Epithelial CellsBiological TransportBronchiCell LineCell-Penetrating PeptidesCell SurvivalDNADrug LiberationGene Transfer TechniquesHumansLungNebulizers and VaporizersNucleic Acid ConformationParticle SizeAerosolsCell-Penetrating PeptidesDNAaerosolcell-penetrating peptidegene deliverylungnebulization

Identifiers

PMID30443858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.